The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat. Participants will receive either NNC4005-0001, which is the treatment being tested, or a placebo, which is a treatment that contains no active medicine. The study will last for about for about 7 to 8 months.
Aged 18-69 years (both inclusive) at the time of signing the informed consent.
Body Mass Index (BMI) of 27.0-40.0 kilogram per square meter (kg/m²) (both inclusive) at screening process.
Hepatic fat fraction greater than or equal to (≥) 8% by magnetic resonance imaging proton density fat fraction (MRI-PDFF) within 17 days prior to dosing.
No prior or present clinical history of metabolic dysfunction-associated steatohepatitis (MASH) diagnosis.
Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
Previous or current use of therapies for MASH or antifibrotic therapies (authorised or within aclinical trial).
Use of high-dose vitamin E [greater than (>) 800 international unit (IU) per day], glucagon-like peptide-1 (GLP-1) agonists (such as liraglutide, dulaglutide, or semaglutide), glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists (such as tirzepatide), or pioglitazone within 6 months prior to screening.
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) levels greater than or equal (≥) 1.5× Upper Limit of Normal (ULN) at screening.